Gene genius that cuts out the need for vivisection: Molecular biologists now play a key role in drug research, says Ruth McKernan

IN THE race for better drugs, pharmaceutical companies are betting on 'gene jockeys' - an American term for those who cut and paste DNA, the molecule of life itself - to develop new drugs. They have found that by cutting up DNA, they do not have to cut up laboratory animals.

Five years ago most companies did not have such wizards. Now the gene jockeys are leading the field in three key areas of drug research: brain disorders, cancer and chronic inflammatory diseases such as arthritis and asthma. Before, pharmacologists might have identified an active compound by its ability to trigger a reaction in an isolated piece of animal tissue, or by the compound's effect on mice. Most drugs now coming on to the market will have taken more than 10 years to develop, and so many of them will have been developed in this way. The techniques of the gene jockeys frequently allow scientists to avoid using animals in the process of drug development.

Most drugs act by binding to specific targets on the surface of cells, called receptors. One problem in drug research is that most cells die when they are removed from their natural surroundings in the body - only a very few types can be cultured for study in the laboratory. The gene jockeys have found a way of getting round this problem.

The recipe that a cell follows to make a receptor is carried by a corresponding gene. Once the gene has been identified, scientists can transfer it from its 'natural' host cell into a cell that will grow in the laboratory. The engineered cell will then 'express' the gene, by growing the appropriate receptor.

In this way, the gene jockeys can persuade human proteins - including human cell surface receptors - to grow in cells derived from completely different organisms. Their colleagues intent on the search for new drugs can then try the effect of thousands of chemicals on the receptors embedded in the engineered cells - a process called 'screening' - to search for an active drug.

Leslie Iversen, director of Merck Sharp & Dohme's Neuroscience Research Centre in Harlow, Essex, says: 'Molecular genetics has allowed the drug discovery process to leap forward in many respects. The amazing thing to me is that we can have a protein which doesn't just resemble, it actually is the human brain receptor transferred into a cultured cell that has been designed by scientists.

'Although this is an entirely artificial system, it is a living, immortalised human receptor that we can put in the freezer and retrieve at any time. It is an enormous advance.'

The search for drugs to treat brain disorders has centred on compounds that either enhance or block the action of the naturally occurring 'chemical messengers' or neurotransmitters, one of the means by which cells communicate with each another. For brain disorders, one unexpected advantage of the application of molecular genetics has been the discovery that for each chemical messenger there is a huge diversity of receptors - much greater than scientists had thought.

For example, the Valium-type drugs act on a specific receptor in brain cells. Scientists have discovered that instead of the two types of brain cell receptor identified by the old-fashioned methods, there are now at least 10 times that many. This has encouraged them to believe that by screening compounds on immortalised cells containing various forms of the receptor they will be able to find better tranquillisers, without the side-effects that have dogged the present generation of drugs.

Other companies are adopting the same approach. Glaxo considers the change in research methods important enough to employ a scientist solely to retrain its traditional pharmacologists in current genetic techniques.

In the search for drugs with the potential to prevent chronic inflammatory diseases, scientists at Glaxo have developed a simplified screening procedure that reproduces the critical early stages of inflammation in the laboratory. These initial reactions are common to many disorders, including arthritis, asthma and ulcerative colitis.

Allan Baxter, director of cellular and molecular sciences at Glaxo, and his team have been trying to find ways of preventing white blood cells migrating from blood vessels into other tissues, where they can cause trouble. The first stage depends on specific receptors on the surface of white blood cells sticking to complementary adhesion molecules on blood vessels. The accumulating white blood cells trigger a complex series of events that results in the inflammatory response. In recent years, potential anti-inflammatory drugs have been sought by injecting compounds into a surface blood vessel of an animal and watching the response.

Researchers now use artificially produced adhesion molecules by transferring the gene coding for the human form into a virus or bacteria, which then produces large amounts of the molecule. Scientists coat glass plates with the molecules, then add human blood cells. Potential drugs prevent blood cells from sticking to the plate. Procedures of this type now underlie most of their drug research programmes.

At the Wellcome Research Laboratories, the search for anti- cancer drugs also depends on engineered cells. A cell becomes cancerous when one of the proteins essential for regulating its normal growth is mutated and goes out of control. Instructions for making the aberrant protein are encoded in an oncogene (cancer-causing gene). When an oncogene is put into a normal cell in the laboratory, rather than growing as a smooth flat layer, the cell takes on very different characteristics. Normal cells grow like a smoothly plastered surface, but cells engineered to contain the oncogene would be the equivalent of a badly Artexed ceiling, with large textured swirls and lumps falling off. The Wellcome scientists test chemicals for their ability to convert cells back to their original state.

'We have used this cell system to screen for agents which work against breast cancer and colon cancer, where one of the aberrant genes has been identified. Compounds identified in this way are now in the early stages of development,' says Martin Page, of Wellcome's cell biology department.

Multiple brain receptors, cell adhesion molecules and cancer-causing genes are just three examples whereby molecular biologists have translated new scientific knowledge into real practical advances in the search for better drugs.

'The more we use the techniques of molecular biology, we realise that, in the past, drugs have been developed in the absence of real knowledge about the receptors with which they interact,' Dr Baxter says.

The writer is a senior research neurobiologist with the pharmaceutical company Merck Sharp and Dohme and has been working as the 1992 British Association Media Fellow at the 'Independent'.

Start your day with The Independent, sign up for daily news emails
Arts and Entertainment
Lou Reed distorted the truth about his upbringing, and since his death in 2013, biographers and memoirists have added to the myths
musicThe truth about Lou Reed's upbringing beyond the biographers' and memoirists' myths
News
people
News
Ed Miliband received a warm welcome in Chester
election 2015
Life and Style
Apple CEO Tim Cook announces the Apple Watch during an Apple special even
fashionIs the iWatch for you? Well, it depends if you want for the fitness tech, or the style
ebooks
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Recruitment Genius: Project Implementation Executive

£18000 - £23000 per annum: Recruitment Genius: They work with major vehicle ma...

Recruitment Genius: Chiropractic Assistant

£16500 per annum: Recruitment Genius: A Chiropractic Assistant is needed in a ...

Recruitment Genius: Digital Account Executive - Midlands

£18000 - £26000 per annum: Recruitment Genius: They work with major vehicle ma...

Recruitment Genius: Web Developer

£28000 - £30000 per annum: Recruitment Genius: This company provides coaching ...

Day In a Page

NHS struggling to monitor the safety and efficacy of its services outsourced to private providers

Who's monitoring the outsourced NHS services?

A report finds that private firms are not being properly assessed for their quality of care
Zac Goldsmith: 'I'll trigger a by-election over Heathrow'

Zac Goldsmith: 'I'll trigger a by-election over Heathrow'

The Tory MP said he did not want to stand again unless his party's manifesto ruled out a third runway. But he's doing so. Watch this space
How do Greek voters feel about Syriza's backtracking on its anti-austerity pledge?

How do Greeks feel about Syriza?

Five voters from different backgrounds tell us what they expect from Syriza's charismatic leader Alexis Tsipras
From Iraq to Libya and Syria: The wars that come back to haunt us

The wars that come back to haunt us

David Cameron should not escape blame for his role in conflicts that are still raging, argues Patrick Cockburn
Sam Baker and Lauren Laverne: Too busy to surf? Head to The Pool

Too busy to surf? Head to The Pool

A new website is trying to declutter the internet to help busy women. Holly Williams meets the founders
Heston Blumenthal to cook up a spice odyssey for British astronaut manning the International Space Station

UK's Major Tum to blast off on a spice odyssey

Nothing but the best for British astronaut as chef Heston Blumenthal cooks up his rations
John Harrison's 'longitude' clock sets new record - 300 years on

‘Longitude’ clock sets new record - 300 years on

Greenwich horologists celebrate as it keeps to within a second of real time over a 100-day test
Fears in the US of being outgunned in the vital propaganda wars by Russia, China - and even Isis - have prompted a rethink on overseas broadcasters

Let the propaganda wars begin - again

'Accurate, objective, comprehensive': that was Voice of America's creed, but now its masters want it to promote US policy, reports Rupert Cornwell
Why Japan's incredible long-distance runners will never win the London Marathon

Japan's incredible long-distance runners

Every year, Japanese long-distance runners post some of the world's fastest times – yet, come next weekend, not a single elite competitor from the country will be at the London Marathon
Why does Tom Drury remain the greatest writer you've never heard of?

Tom Drury: The quiet American

His debut was considered one of the finest novels of the past 50 years, and he is every bit the equal of his contemporaries, Jonathan Franzen, Dave Eggers and David Foster Wallace
You should judge a person by how they peel a potato

You should judge a person by how they peel a potato

Dave Hax's domestic tips are reminiscent of George Orwell's tea routine. The world might need revolution, but we like to sweat the small stuff, says DJ Taylor
Beige is back: The drab car colours of the 1970s are proving popular again

Beige to the future

Flares and flounce are back on catwalks but a revival in ’70s car paintjobs was a stack-heeled step too far – until now
Bill Granger recipes: Our chef's dishes highlight the delicate essence of fresh cheeses

Bill Granger cooks with fresh cheeses

More delicate on the palate, milder, fresh cheeses can also be kinder to the waistline
Aston Villa vs Liverpool: 'This FA Cup run has been wonderful,' says veteran Shay Given

Shay Given: 'This FA Cup run has been wonderful'

The Villa keeper has been overlooked for a long time and has unhappy memories of the national stadium – but he is savouring his chance to play at Wembley
Timeless drama of Championship race in league of its own - Michael Calvin

Michael Calvin's Last Word

Timeless drama of Championship race in league of its own